Compositions comprising novel ppar ligands and anti-hyperlipemic agents

Abstract

Methods are provided for treating or preventing conditions comprising hypertension and dyslipidemia using antihyperlipemic agents and compounds that antagonize the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs) and lower triglycerides or elevate blood HDL-cholesterol. Compositions are provided for treating or preventing conditions comprising hypertension and dyslipidemia, comprising antihyperlipemic agents which lower triglycerides and inhibit cholesterol synthesis such as statins, and compounds that antagonize or block the angiotensin II type 1 (AT1) receptor, activate PPARs and lower triglycerides or elevate blood HDL-cholesterol such as sartans.

1 - 58 . (canceled) 
     
     
         59 . A method for decreasing an incidence of a metabolic disorder in a human consisting of administering to the human in need thereof, a therapeutically effective amount of a sartan or an ester of the sartan, wherein the metabolic disorder is type 2 diabetes mellitus or metabolic syndrome, and wherein the sartan is sufficient to increase an activity of the peroxisome proliferator activated receptor gamma (PPAR-γ) and has the following formula: 
       
         
           
           
               
               
           
         
       
     
     
         60 . The method of  claim 59 , wherein the sartan is administered at a total effective daily dose between 20 mg to 1,000 mg. 
     
     
         61 . The method of  claim 59 , wherein the sartan is administered at a total effective daily dose between 5 mg to 300 mg.